Novartis AG (NYSE:NVS) Shares Bought by Heritage Family Offices LLP

Heritage Family Offices LLP grew its stake in Novartis AG (NYSE:NVS) by 1.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,107 shares of the company’s stock after buying an additional 112 shares during the quarter. Heritage Family Offices LLP’s holdings in Novartis were worth $594,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Integral Health Asset Management LLC grew its holdings in Novartis by 33.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock worth $31,938,000 after acquiring an additional 75,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novartis by 115.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after purchasing an additional 124,111 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Novartis by 343.5% during the second quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock worth $70,652,000 after purchasing an additional 509,567 shares in the last quarter. CWA Asset Management Group LLC increased its holdings in Novartis by 20.1% in the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after buying an additional 5,164 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in Novartis by 135.5% in the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock valued at $4,598,000 after buying an additional 22,998 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Trading Down 0.3 %

NYSE:NVS opened at $99.05 on Thursday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The stock’s 50 day moving average price is $101.13 and its 200 day moving average price is $109.19. The company has a market capitalization of $202.46 billion, a PE ratio of 11.50, a P/E/G ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period last year, the firm posted $1.74 earnings per share. On average, research analysts anticipate that Novartis AG will post 7.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NVS shares. BMO Capital Markets increased their price objective on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.